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Edited by Varda RotterAbstract MicroRNAs (miRNAs) are a recently discovered
family of 18–24 nucleotide non-coding RNAs that can negatively
regulate target mRNAs. All studied multicellular eukaryotes uti-
lize miRNAs to regulate basic cellular functions including prolif-
eration, diﬀerentiation, and death. It is now apparent that
abnormal miRNA expression is a common feature of human
malignancies. This review discusses the various cancer-relevant
miRNAs (oncomirs) especially in cervical tumorigenesis and
the potential role of oncomirs as therapeutic agents and targets
for the treatment of cervical cancer.
 2008 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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MicroRNAs or miRNAs, initially discovered in the early
1990s as small, non-coding RNA molecules able to regulate
expression of key genes involved in development, have now
been associated with the regulation of diverse physiological
processes including cell diﬀerentiation and cell division [1].
Over 500 human miRNA molecules have been identiﬁed so
far. In 1993, Rosalinda et al. discovered the ﬁrst microRNA
(miRNA) named lin-4 and the term introduced for the ﬁrst
time in a set of three articles that appeared in the October
2001 issue of Science. It is known that miRNAs are highly con-
served molecules; for example, the complete mature miRNA
sequence of let-7, isolated the ﬁrst time in Caenorhabditis
elegans, has been evolutionarily conserved from worms to hu-
mans. Thousands of miRNAs have been identiﬁed in nema-
todes, insects, birds, amphibians, ﬁshes, plants, mammals,
and even viruses using molecular cloning and bioinformatics
prediction strategies [2–4]. Bioinformatics approaches have
proved to be very useful toward this goal in guiding the exper-
imental investigation. Computer-based prediction approaches
of miRNAs and their targets, and biological validation tech-Abbreviations: miRNAs, microRNAs; HPV, human papillomavirus;
og, oncogenic; tsg, tumor suppressor gene; EBV, Epstein-Barr virus;
KSHV, Kaposi sarcoma-associated herpesvirus; HSV, Herpes Simplex
Virus; SV40, Simian virus 40
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doi:10.1016/j.febslet.2008.11.011niques for ascertaining these predictions, currently play a cen-
tral role in the discovery of miRNAs and in elucidating their
function [5,6].
A number of microRNAs, encoded in the human genome
have been shown to be intrinsically involved in cancer patho-
genesis and progression. There is suﬃcient evidence that some
of these ‘‘oncomirs’’, as these cancer-associated miRNAs are
sometimes referred to, possess a tumor-suppressive/pro-
apoptotic role while others have anti-apoptotic/proliferation
promoting roles in the cell [7]. It has also been reported that
key miRNAs have regulatory roles in inﬂammation and metas-
tasis [8]. A number of recent studies have reported miRNA
dysregulation in various forms of cancer. Abnormalities in
miRNA expression have been implicated in several forms of
solid tumors such as cervical [9], breast [10], colorectal [11],
lung [12] and also in at least two forms of leukemia [13]. Fun-
damental relationships exist between the pathogenesis of can-
cer and miRNA dysregulation, as demonstrated in a large,
recent study, where a set of 127 mammalian microRNAs were
expression proﬁled across a vast panel of clinical samples [14].
This study strongly suggested that the ‘‘developmental history
of a tumor is reﬂected in its miRNA expression patterns’’. A
recent study proved the involvement of a new class of non-cod-
ing RNAs (ncRNAs), named ultra conserved genes, in human
cancers and found that miRNAs can directly target and regu-
late the expression of these ncRNAs [15]. Among the ﬁrst clues
for their involvement in cancers was the observation that miR-
NAs are frequently located in cancer-associated genomic re-
gions, which include minimal regions of ampliﬁcation, loss of
heterozygosity, fragile sites, and common breakpoint regions
in or near oncogenes or tumor suppressor genes [16]. The dis-
covery of the involvement of microRNAs in the initiation and
progression of human cancer may provide additional targets
for anticancer treatment design.2. Cervical cancer
Cervical cancer is one of the most common cancers in wo-
men worldwide, with an estimated global incidence of
470000 new cases and approximately 233000 deaths per year
[17,18]. Cervical cancer is the leading cause of death from can-
cer in many low resource countries where widespread screening
by cervical cytology is still unavailable. The incidence is lower
in developed countries as a consequence of cervical screening
and of ongoing active health education programs. The causal
relationship between high-risk HPV (HR-HPV) infection and
cervical cancer has been well documented in epidemiologicalblished by Elsevier B.V. All rights reserved.
Table 2
MicroRNAs underexpressed in cervical cancer cell lines.
miRNA Chromosome Putative function
hsa-miR-126 09 og/tsg
hsa-miR-145 05 og/tsg
hsa-miR-451 17 og/tsg
hsa-miR-195 19 og/tsg
hsa-miR-143 05 og/tsg
hsa-miR-199b 09 og/tsg
hsa-miR-1 01 og/tsg
hsa-miR-495 14 og/tsg
hsa-miR-497 17 og/tsg
hsa-miR-133b 06 og/tsg
hsa-miR-223 X og/tsg
hsa-miR-146a 05 og/tsg
hsa-miR-126-AS 09 og/tsg
hsa-miR-150 19 og/tsg
hsa-miR-376a 14 og/tsg
hsa-miR-214 01 og/tsg
hsa-miR-487b 14 og/tsg
hsa-miR-10b 02 og/tsg
hsa-miR-218 04 og/tsg
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HPV18, and HPV31, have been detected in up to 99.7% of
cervical squamous cell carcinomas and 94–100% of cervical
adeno- and adenosquamous carcinomas [19,20]. The high-risk
HPV oncoproteins, E6 and E7, contribute to cervical carcino-
genesis by inactivating the cellular tumor suppressor proteins
p53 and pRb, respectively [21–23].
Many authors have reported that each cancer tissue has a
speciﬁc microRNA signature and microRNA based cancer
classiﬁcation is a very eﬀective and potential tool [14]. It is
interesting to speculate that the variations in miRNA expres-
sion in cervical cancer cell lines contribute to deregulation of
the cell cycle regulatory pathway in cervical cancer. Thus
miRNA expression patterns may serve as potential biomarkers
of pre-invasive cervical disease and potential therapeutic tar-
gets. There are currently no drugs in the clinic that speciﬁcally
target HPV and the need to discover more eﬀective and more
speciﬁc inhibitors of such key molecular targets is clearly
justiﬁed.
hsa-miR-149 02 og/tsg
hsa-miR-203 14 og/tsg3. MiRNA expression proﬁle in cervical cancer cell lines
Wang et al. found that of 174 miRNAs (including the novel
miR-193c) which could be grouped into 46 diﬀerent miRNA
species, miR-21, miR-24, miR-27a, and miR-205 were most
abundant in cervical cancer- or cervical intraepithelial neopla-
sia-derived cell lines [24]. There was however no correlation
observed between their expression with the presence or absence
of an integrated or episomal HPV genome. All cell lines exam-
ined contained no detectable miR-143 and miR-145. HPV-in-
fected cell lines expressed a diﬀerent set of miRNAs when
grown in organotypic raft cultures as compared to monolayer
cell culture, including expression of miR- 143 and miR-145.
Suggesting a correlation between miRNA expression and tis-
sue diﬀerentiation. miRNA array analyses for age-matched
normal cervix and cervical cancer tissues, in combination with
Northern blot veriﬁcation identiﬁed deregulated miRNAs in
cervical cancer tissues. Downregulation of with miR-126,
miR-143, and miR-145, miR-218, and miR-424 (Table 2)Table 1
MicroRNAs overexpressed in cervical cancer cell lines.
miRNA Chromosome Putative function
hsa-miR-210 11 Oncogenic
hsa-miR-182 07 og/tsg
hsa-miR-183 08 og/tsg
hsa-miR-200c 12 Tumor suppressor
hsa-miR-203 14 og/tsg
hsa-miR-193b 16 Oncogenic
hsa-miR-34a 01 og/tsg
hsa-miR-31 11 og/tsg
hsa-miR-210 11 og/tsg
hsa-miR-27a 19 og/tsg
hsa-miR-503 X og/tsg
hsa-miR-27b 09 og/tsg
hsa-miR-199a 19 og/tsg
hsa-miR-199b 09 og/tsg
hsa-miR-145 05 og/tsg
hsa-miR-133a 18 og/tsg
hsa-miR-133b 06 og/tsg
hsa-miR-214 01 og/tsg
hsa-miR-127 14 og/tsgand upregulation of miR-15b, miR-16, miR-146a, and miR-
155 (Table 1). Functional studies showed that both miR-143
and miR-145 are suppressive to cell growth. When introduced
into cell lines, miR-146a was found to promote cell prolifera-
tion. The authors hypothesized that downregulation of miR-
143 and miR-145 and upregulation of miR-146a play a role
in cervical carcinogenesis [24].
Downregulation of miR-143 and miR-145 has been found in
several other cancers, including colorectal cancer [25], B-cell
lymphoma [26], and recently in cervical cancer [27,28]. Thus,
ﬁnding is important for understanding mechanisms by which
miR-143 and miR-145 are involved in carcinogenesis. Various
studies show that miR-46a is a NF-kappaB-dependent gene
[29–31]. Expression of miR-146a appears to vary in diﬀerent
cancer tissues. Increased level of miR-146a was observed in
Burkitts lymphoma lines with EBV-LMP1 expression
[30,32], but decreased levels seen in hormone-refractory pros-
tate cancer [31] and papillary thyroid carcinoma [33]. The
authors concluded that upregulation of miR-146a expression
in cervical cancer is beneﬁcial for cancer growth since intro-
duction of miR-146a into cancer cells increased cell doubling
time and promoted cell proliferation. Moreover, Wang et al.
were unable to identify a single HPV16-derived miRNA from
HPV16 + CaSki cells, although other nuclear DNA viruses do
encode miRNAs [34], including EBV [35]; KSHV [36–38];
HSV-1 [39,40]; and SV40 [41]. Recent reports have suggested
that miRNAs contribute to a variety of cell functions and
are involved in the development of human cancers [42]. miR-
NAs have been also characterized recently as potential onco-
genes that promote the development of human B-cell
lymphoma (miR-17-92 cluster) [43] and the proliferation and
tumorigenesis of primary human cells (miR-372 and miR-
373) by neutralizing p53-mediated CDK inhibition [44]. An-
other study suggested that overexpression of miR-17-5p,
miR-20a, miR-21, miR-92, miR-106a, and miR-155 could be
considered an miRNA signature of solid tumors [45]. Eighteen
miRNAs were upregulated where 15 were downregulated in
cervical cancer tissues. The increased expression of miR-15b,
miR-16, miR-146a, miR-155, and miR-223 observed in cervi-
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of other human cancers: miR-15 and miR-16 regulate apopto-
sis by targeting BCL2 [46] and their mutation has been associ-
ated with chronic lymphocytic leukemia [47]; miR-16 is also
involved in control of cytokine RNA instability [48]; miR-
146b levels are highly increased in papillary thyroid carcinoma
[33]; miR-155 has recently been implicated in the development
of lymphoblastic leukemia/high-grade lymphoma [49] and lung
cancer [50] and in the regulation of human ﬁbroblast angioten-
sin II type 1 receptor expression [51]; miR-223, along with the
transcription factors C/EBPa and NFI-A, participates in regu-
lation of granulocytic diﬀerentiation by suppressing the tran-
scription of NFI-A mRNA [52].4. Altered miRNA expression in cervical carcinomas
Lee et al. identiﬁed altered miRNA expression in early stage
ISCCs and normal epithelial tissues of the cervix. The ﬁndings
suggest that miR-127 may be a marker for lymph node metas-
tasis of ISCCs and that miR-199a may be a potential therapeu-
tic target for cervical cancer therapy [9]. Tissue-speciﬁc
patterns of miRNA expression have been recently reported;
they are thought to reﬂect embryologic development [53]. Sev-
eral reports showed that speciﬁc overexpression or underex-
pression of miRNAs diﬀer according to the particular tumor
types [43]. Most human miRNAs are found between protein-
coding genes; approximately one-third are located within the
introns of annotated mRNAs. These intronic miRNAs are
usually in the same orientation as the pre-mRNA, and thus,
could be under the control of the promoter driving the primary
mRNA transcript [54]. Despite the uncertainty regarding the
functional eﬀects of miRNAs, the miRNA expression proﬁle
may be used as a prognostic marker for clinical aggressiveness
of human cancer. One such example is chronic lymphocytic
leukemia. Calin et al. reported a miRNA expression signature
composed of 13 mature miRNAs that were associated with
prognostic factors and disease progression [55]. Recently, a
study on pancreatic endocrine and acinar tumors revealed that
the overexpression of miR-21 is strongly associated with both
a high Ki67 proliferation index and the presence of liver metas-
tasis [56]. The expression of miR-127 was signiﬁcantly higher
in the group of ISCCs with lymph node metastasis than in
those without metastasis. In addition, there were two major
classes of early stage ISCC, identiﬁed by hierarchical cluster-
ing, which showed diﬀerences in lymph node metastasis.
Rather, loss- or gain-of-function of speciﬁc miRNAs seems
to be a key event in the genesis of a variety of cancers. There-
fore, miRNAs might be potential targets for therapy. This
ﬁnding points toward miRNAs as tumor suppressors and
highlights their potential as a new kind of regenerative medi-
cine to treat cancer.5. Conclusion and future directions
It has been less than 8 years since the discovery of the ﬁrst
miRNAs, and it is likely that many others await discovery.
The in vivo study provides an exciting step towards miRNA
therapy, and the potential for designing molecular leads based
on the modulation of miRNAs seems good. The eﬀects of the
antagomirs on the protein level, however, were only examinedfor a few enzymes connected with cholesterol metabolism [57].
The eﬃcient development and delivery of suﬃcient amount of
antagomir into the proper target cell without overt toxicity re-
quires ﬁne tuning of molecular technology before it can be
tried clinically. In addition, unwanted side eﬀects to such ther-
apeutic agents may occur over the long term. As miRNA-
based therapies begin to be evaluated in clinical studies, the
next few years will test the promise of relevant drugs, allowing
us to combine the speciﬁcity of siRNA and the mismatch tol-
erance of miRNA. Still although studies of oncomirs are at its
dawn, a new era of anticancer treatment with these natural
molecules can be forecast, bringing new insights in neoplastic
disease and new promising therapeutic strategies.Acknowledgement: This study is supported by Department of Biotech-
nology, Government of India (No. BT/PR5435/BID/07/095/2004).References
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